Profile Image

Staff Profile

Edit

Career Summary

Biography

For more than 15 years, Dr Xu Dong Zhang has focused on translational melanoma research with an overall aim to overcome resistance of metastatic melanoma to treatment. He is currently a Professor heading the Melanoma Research Laboratory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer. Professor Zhang has published more than 80 manuscripts in his research career. The H Factor (Index) of his publications is currently 31. In addition, He has presented my work in a large number of international and national conferences and institutional seminars, with many attendances as an invited speaker. As a chief investigator, He has attracted a large sum of funding for his research. In the past 3 years since, he was awarded an NHMRC Senior Research Fellowship (2011), and successfully renewed, for the third consecutive time, a Cancer Institute NSW (CINSW) Fellowship (2011) that is now awarded in the form of a top-up to the NHMRC Fellowship. He is a chief investigator of a translational melanoma research program grant awarded in 2011 by CINSW, and, as Chief investigator A, he has received 2 NHMRC project grants and 4 Cancer Council NSW project grants since 2009. In addition, He is a co-chief investigator of another NHMRC project grant and a chief investigator of a number of competitive grants from other funding bodies. Professor Zhang’s research has drawn considerable attention in the cancer research community worldwide and his contribution to melanoma research is highly regarded nationally and internationally. He regularly review manuscripts for high impact journals including Cancer Research and Oncogene, and assess grant applications for international and national funding bodies, such as Medical Research Council UK and NHMRC. He was a Grant Review Panel (GRP) member of NHMRC in 2011 and a a panel member of Cancer Australia in 2013. His research has also drawn extensive attention from the general public, with the highlight being 8 interviews by media including the ABC in the past 3 years. His research excellence has enabled me to establish productive collaborations with other researchers, both within academia and commercial organizations. In addition, I provide regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of highly ranked universities and institutes in China. He has proven himself to be highly competent in supervision of research high degree students and junior researchers. Since he received my first conjoint appointment in 2005 from the University of Newcastle, two PhD students have completed their studies in excellent fashion under my supervision. During the past 3 years, two postdoctoral researchers have successfully obtained NHMRC Postdoctoral Training Fellowship under his supervision. At the current time, he is the principal supervisor of 5 PhD candidates, and a co-supervisor of another two. Professor Zhang is a Co-Director of the Priority Research Centre (PRC) for Cancer of the Faulty of Health, and a Deputy Director of the Cancer Program of Hunter Medical Research Institute. He is also a member of various scientific and administering committees, including the HMRI Research Council, the Research Council of Hunter Translational Cancer Research Unit, and the Analytical and Biomolecular Research Facility Advisory Group of University of Newcastle.

Qualifications

  • PhD, University of Sydney, 04/05/2002
  • Bachelor of Medicine, Shanxi Medical University PR China, 31/08/1986

Research

Research keywords

  • Carcinogenesis
  • Cell Death
  • Oncology
  • Signal Transduction

Research expertise

Melanoma is the most serious form of skin cancer that is often referred to as Australia's national cancer as Australia has the highest incidence of melanoma in the world. However, there is currently no curative treatment once the disease spreads beyond the original site. To address this major Australian health problem, Professor Xu Dong Zhang has been working on translational research on melanoma with a focused theme of “overcoming resistance of metastatic melanoma to treatment” for more than 15 years. In particular, he has been recognized nationally and internationally for his significant contribution to understanding resistance mecahnisms of melanoma cells to apoptosis, a form of cell death that is the main mechanism of killing of cancer cells by most anti-cancer therapeutic drugs.

Professor Zhang is currently leading the Melanoma Research Laboraotory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer.

He pioneered two areas of the the melanoma research field, overcoming resistance of melanoma cells to apoptosis induced by TRAIL (a soluble factor that can be produced by immune cells and selectively kill cancer cells without affecting normal tissues) and examining the response of melanoma cells to a cellular stress condition termed ER stress. While his leading role in these areas has been consolidated in recent years, he has initiated a number of new projects that advance the frontier of melanoma resaerch. These include projects to address the questions “what regulates sensitivity of melanoma cells to apoptosis induced by inhibition of intracellular pro-survival signalling pathways?”, “how do a group of proteins called polyphosphate phosphatase affect melanoma cell malignancy?”, “why does the tumour suppressor p53 not function to suppress melanoma?”, and “is there any relationship between obesity and melanoma development, progression, and resistance to treatment?”.

Professor Zhang’s research program is closely allied with the research scheme of the Melanoma Institute Australia (MIA). This not only allows my team to have full access to the largest repository of melanoma-related bio-samples with linked follow-up data in the world, but also fast tracks our scientific exchanges with melanoma researchers nationally and internationally. In addition, my research program is integrated into the research strategy of the Priority Research Center (PRC) for Cancer of UoN and that of the Cancer Research Program (CRP) of the Hunter Medical Research Institute (HMRI). This not only facilitates collaborations between his research team and other local cancer researchers, but also enables him to contribute his research expertise broadly to other cancer research programs in Newcastle.

Languages

  • English
  • Mandarin

Fields of Research

CodeDescriptionPercentage
111200Oncology And Carcinogenesis75
060199Biochemistry And Cell Biology Not Elsewhere Classified25

Memberships

Body relevant to professional practice.

  • Member - American Association for Cancer Research (AACR)
  • Member - the Analytical and Biomolecular Research Facility (ABRF) Advisory Group of University of Newcastle

Committee/Associations (relevant to research).

  • Member - Executive Committee of Hunter Translational Cancer Research Unit (TCRU)
  • Member - the Hunter Medical Research Institute (HMRI) Cancer Research Program (CRP) Steering Committee
  • Member - the ERA 2012 Cluster Advisory Group of University of Newcastle

Editorial Board.

  • Member - World Journal of Gastrointestinal Oncology
  • Member - The Scientific World Journal
  • Member - the Chinese Journal of Stem Cells

NHMRC Committee

  • Member - Grant Review Panel

Appointments

Senior Reserch Fellow
NHMRC (Australia)
01/01/2011
Research Fellow
Cancer Institute NSW (Australia)
01/01/2011
Research Fellow
Cancer Institute NSW (Australia)
01/01/2008 - 01/12/2010
Resaerch Fellow
Cancer Institute NSW (Australia)
01/01/2006 - 01/12/2008
Senior Brawn Research Fellow
University of Newcastle (Australia)
01/01/2011

Awards

Research Award.

2004Young Resaerch of the Year
Hunter Medical Research Institute (Australia)
To recognize my achievement in cancer research.

Invitations

Induction of apoptosis: the key for successful treatment of melanoma by mutant BRAF inhibitors?
The BIT Science’ 4rd PEPCON Conference, China (Invited Presenter)
2012
Adaptation to ER stress as a driver of increased expression of Mcl-1 with melanoma progression.
7th Annual International Melanoma Congress, Australia (Invited Presenter)
2010
Up-regulation of Mcl-1 by the Unfolded Protein Response is Critical for Survival of Melanoma Cells upon ER stress.
7th World Congress on Melanoma, Austria (Invited Presenter)
2009
Up-regulation of Mcl-1 by the Unfolded Protein Response is Critical for Survival of Melanoma Cells upon ER stress.
XXth IPCC & Vth IMRC, Japan (Invited Presenter)
2008

Collaboration

Professor Zhang’s research excellence has enabled him to establish productive collaborations with other researchers, both within academia and commercial organizations. His research team has successfully completed contract work for the biocompanies, Peplin Biotechnology and Novogene Biotechnology on testing new drugs on melanoma cells. His collaborations with AstraZeneca, Roche, and GlaxoSmithKline (GSK) on testing novel targeted therapeutics are ongoing. His collaborations with Drs Rick Thorne, Nicole Verrills, Nicholas Bowden, Ming Yang, Professors Rodney Scott locally, Professors Richard Kefford and Richard Scolyer and Dr Helen Rizos at the University of Sydney, Drs Tao Liu and Belamy Cheung at the University of New South Wales, and Dr Jiezhong Chen at the University of Wollongong are also continuing.

Professor Zhang provides regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of universities and institutes in China. He has been an honorary professor of Anhui Medical University since 2003, and received another honorary professorship from the Fourth Military Medical University in 2010. He was honored with a third professorship in China by Shanxi Cancer Hospital/Shanxi Cancer Institute in 2012. He was also appointed as an honorary director of the Cellular and Molecular Biology Laboratory of the same hospital/institute.

Aside from the Chinese universites and institues where Professor Zhang is an honorary professor, He has also established collaborations with researchers from other universities in China, including the Sun Yat-sen University in Guangzhou (Professors Xiao Shi Zhang and Xiao Feng Zhu), the Sichuan University in Chengdu (Dr Yu Fang Wang), and the University of Science and Technology of China in Hefei (Professor Main Wu). All these universities are among top-20 universities in China according to 2011 ranking (the Sun Yat-sen University is ranked 10; the Sichuan University, 12; and the University of Science and Technology of China, 18). These collaborations have proven to be productive and mutually beneficial as demonstrated by collaborative publications and conference presentations.

Administrative

Administrative expertise

Dr Zhang acts as a team leader of a research group at the oncology and Immunology Unit that is specialized in research on melanoma biology

Teaching

Teaching expertise

Tumor biology; Tumor Immunology; Apoptosis; Signaling transduction.

Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Chapter (5 outputs)

YearCitationAltmetricsLink
2012Lai FS, Jin L, Gallagher S, Mijatov B, Zhang XD, Hersey P, 'Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors', Advances in Pharmacology, Academic Press, Maryland Heights, MO 27-43 (2012) [B1]
2012Hersey P, Zhang XD, 'Targeting apoptotic pathways in melanoma', Targeted Therapeutics in Melanoma, Humana Press, New York 125-153 (2012) [B1]
2008Hersey P, Zhang XD, Mhaidat N, 'Overcoming resistance to apoptosis in cancer therapy', Programmed Cell Death in Cancer Progression and Therapy, Springer, Berlin 105-126 (2008) [B1]
2006Hersey P, Zhang XD, Mhaidat N, 'Overcoming Resistance to Apoptosis in Cancer Therapy', Programmed Cell Death in Cancer Progression and Therapy, Springer, Berlin, Germany 105-126 (2006) [B1]
2005Hersey P, Zhang SY, Zhang XD, 'Regulation of trail receptor expression in human melanoma', Death Receptors in Cancer Therapy, Humana Press, New York 175-187 (2005) [B1]
Show 2 more

Journal article (109 outputs)

YearCitationAltmetricsLink
2014Chi M, Chen J, Ye Y, Tseng H-Y, Lai F, Tay KH, et al., 'Adipocytes Contribute to Resistance of Human Melanoma Cells to Chemotherapy and Targeted Therapy', CURRENT MEDICINAL CHEMISTRY, 21 1255-1267 (2014) [C1]
2014Ye Y, Li Q, Ge Y-M, Zhang L-J, Zhang X-D, 'The effects of PIB5PA on migration and invasion of human melanoma cells', Tumor, 34 487-493 (2014)
2014Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, et al., 'Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor', ONCOGENE, 33 1158-1166 (2014)
2014Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, et al., 'Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor', Oncogene, 33 1158-1166 (2014)
2014Oliveira CS, de Bock CE, Molloy TJ, Sadeqzadeh E, Geng XY, Hersey P, et al., 'Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.', BMC Cancer, 14 630 (2014)
2014Chi M, Ye Y, Zhang XD, Chen J, 'Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway', DRUG DESIGN DEVELOPMENT AND THERAPY, 8 255-262 (2014)
2014Wu PY, Wang JF, Zhang XD, Guo XY, Zhu J, 'Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone', Human Pathology, 45 1664-1673 (2014)
2014Jiang CC, Croft A, Tseng H-Y, Zhang XD, Guo ST, Jin L, Hersey P, 'Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma', Oncogene, 33 2577-2588 (2014)
2014Croft A, Tay KH, Jiang CC, Lai F, Tseng H-Y, Jin L, et al., 'Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress', Journal of Investigative Dermatology, 134 488-497 (2014)
2014Wu PY, Wang JF, Zhang XD, Guo XY, Zhu J, 'Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone', Human Pathology, (2014)
2014Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, et al., 'Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.', J Natl Cancer Inst, 106 (2014)
2014Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, et al., 'Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor', Oncogene, 33 1158-1166 (2014)
2014Wu P, Cheng YW, Wang JY, Zhang LJ, Zhang XD, 'Inhibition of MEK sensitizes gastric cancer cells to TRAIL-induced apoptosis', Neoplasma, 61 136-143 (2014)
2014Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, et al., 'Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress', JOURNAL OF INVESTIGATIVE DERMATOLOGY, 134 488-497 (2014)
2014Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H, Liu Z, 'Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination.', Autophagy, 10 257-268 (2014)
2014Tay KH, Luan Q, Croft A, Jiang CC, Jin L, Zhang XD, Tseng H-Y, 'Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress', CELLULAR SIGNALLING, 26 287-294 (2014)
2013Li Y, Liu H, Huang YY, Pu LJ, Zhang XD, Jiang CC, Jiang ZW, 'Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 31 1234-1242 (2013) [C1]
2013Ye Y, Li Q, Zhang LJ, Yang S, Hu WL, Tseng H-Y, et al., 'Loss of PI(4,5)P 5-phosphatase A contributes to resistance of human melanoma cells to RAF/MEK inhibitors', Translational Oncology, 6 470-481 (2013) [C1]
2013Sun X-J, Liu H, Zhang P, Zhang X-D, Jiang Z-W, Jiang C-C, 'miR-10b Promotes Migration and Invasion in Nasopharyngeal Carcinoma Cells', ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 14 5533-5537 (2013) [C1]
2013Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, et al., 'PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma', NATURE COMMUNICATIONS, 4 (2013) [C1]
2013Song L, Liu H, Ma L, Zhang X, Jiang Z, Jiang C, 'Inhibition of autophagy by 3-MA enhances endoplasmic reticulum stress-induced apoptosis in human nasopharyngeal carcinoma cells', ONCOLOGY LETTERS, 6 1031-1038 (2013) [C1]
2013Chen J, Chi M, Chen C, Zhang XD, 'Obesity and melanoma: Exploring molecular links', Journal of Cellular Biochemistry, 114 1955-1961 (2013) [C1]
2013Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, et al., 'AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.', Cell Death and Disease, 4 e914 (2013) [C1]
2013Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, et al., 'MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer', ONCOGENE, 32 1910-1920 (2013) [C1]
2013Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK, et al., 'The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance', CARCINOGENESIS, 34 237-247 (2013) [C1]
2013Carlino MS, Gowrishankar K, Pupo GM, Snoyman S, Becker TM, Kefford RF, et al., 'Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma', Molecular Cancer Therapeutics, 12 1332-1342 (2013) [C1]
2013Chen J, Shao R, Zhang XD, Chen C, 'Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics', International Journal of Nanomedicine, 2013 2677-2688 (2013) [C1]
2013Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, et al., 'The histone deacetylase SIRT2 stabilizes Myc oncoproteins', CELL DEATH AND DIFFERENTIATION, 20 503-514 (2013) [C1]
2013Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, et al., 'Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3', CELL DEATH & DISEASE, 4 (2013) [C1]
2013Wroblewski D, Jiang CC, Croft A, Farrelly ML, Zhang XD, Hersey P, 'OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.', PLoS One, 8 e84073 (2013) [C1]
2013Chen J, Zhang XD, Jiang Z, 'The Application of Fungal Beta-glucans for the Treatment of Colon Cancer', ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 13 725-730 (2013) [C1]
2013Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
2013Jiang CC, Croft A, Tseng H-Y, Zhang XD, Guo ST, Jin L, Hersey P, 'Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma', Oncogene, (2013)
2013Dong L, Jin L, Tseng H-Y, Yan XG, Jiang CC, Zhang XD, et al., 'Oncogenic suppression of PHLPP1 in human melanoma', Oncogene, (2013)
2012Zhan Z, Li Q, Wu P, Ye Y, Tseng HY, Zhang L, Zhang XD, 'Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1', Autophagy, 8 109-121 (2012) [C1]
2012Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 e337 (2012) [C1]
2012Tseng HY, Chen L, Ye Y, Tay KH, Jiang CC, Guo ST, et al., 'The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells', Carcinogenesis, 33 1871-1881 (2012) [C1]
2012Lai FS, Jiang CC, Farrelly ML, Zhang XD, Hersey P, 'Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors', Melanoma Research, 22 244-251 (2012) [C1]
2012Xu W-H, Zhang A-M, Ren M-S, Zhang XD, Wang F, Xu X-C, et al., 'Changes of treg-associated molecules on CD4 +CD25 +treg cells in myasthenia gravis and effects of immunosuppressants', Journal of Clinical Immunology, 32 975-983 (2012) [C1]
2012Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al., 'Guidelines for the use and interpretation of assays for monitoring autophagy', Autophagy, 8 445-544 (2012) [C1]
2012Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, et al., 'Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-Mimetic ABT-737', Clinical Cancer Research, 18 783-795 (2012) [C1]
2011Wilmott JS, Zhang XD, Hersey P, Scolyer RA, 'The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers', Pathology, 43 657-671 (2011) [C1]
2011Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
2011Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, et al., 'Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress', Oncogene, 30 3716-3726 (2011) [C1]
2011Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD, 'MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720', Clinical Cancer Research, 17 721-730 (2011) [C1]

Co-authors: Rick Thorne

2011Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, et al., 'MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma', Proceedings of the National Academy of Sciences, 108 15840-15845 (2011) [C1]

Co-authors: Rick Thorne

2011Sadeqzadeh E, De Bock CE, Zhang XD, Shipman KL, Scott NM, Song C, et al., 'Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products', Journal of Biological Chemistry, 286 28181-28191 (2011) [C1]
2010Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, et al., 'Apoptosis of human melanoma cells induced by inhibition of B-RAF(V600E) involves preferential splicing of bim(S)', Cell Death & Disease, 1 e69 (2010) [C1]
2010Tseng H-Y, Jiang CC, Croft A, Croft A, Thorne RF, Yang F, et al., 'Contrasting effects of Nutlin-3 on TRAIL - and Docetaxel-induced Apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells', Molecular Cancer Therapeutics, 9 3363-3374 (2010) [C1]
2010Mao ZG, Jiang CC, Thorne RF, Hersey P, Zhang XD, 'TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4', Apoptosis, 15 1211-1222 (2010) [C1]
2010Thorne RF, Ralston KJ, De Bock CE, Mhaidat NM, Zhang XD, Boyd AW, Burns GF, 'Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum', Biochimica et Biophysica Acta - Molecular Cell Research, 1803 1298-1307 (2010) [C1]
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
2010Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E, et al., 'Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIPL from degradation by the E3 ligase itch in human melanoma cells', Cell Death and Differentiation, 17 1354-1367 (2010) [C1]
2010Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF, Hersey P, 'Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins', Modern Pathology, 23 45-53 (2010) [C1]
2009Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD, 'Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt', Neoplasia, 11 436-447 (2009) [C1]
2009Hersey P, Zhang XD, 'Treatment combinations targeting apoptosis to improve immunotherapy of melanoma', Cancer Immunology, Immunotherapy, 58 1749-1759 (2009) [C1]
2009Zhang XD, Li SC, Fong K-Y, Thumboo J, 'The Impact of Health Literacy on Health-Related Quality of Life (HRQoL) and utility assessment among patients with rheumatic diseases', Value in Health, 12 S106-S109 (2009) [C1]
2009Hersey P, Watts RN, Zhang XD, Hackett J, 'Metabolic approaches to treatment of melanoma', Clinical Cancer Research, 15 6490-6494 (2009) [C1]
2009Jiang CC, Mao ZG, Kiejda KA, Hersey P, Zhang XD, 'Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells', Carcinogenesis, 30 197-204 (2009) [C1]
2009Zhang LJ, Chen S, Wu P, Hu CS, Thorne RF, Luo CM, et al., 'Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells', Cancer Letters, 274 40-46 (2009) [C1]
2009Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD, 'Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax', Neoplasia, 11 945-955 (2009) [C1]
2009Zhuang L, Scolyer RA, Lee CS, McCarthy SW, Cooper WA, Zhang XD, et al., 'Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma', Histopathology, 54 462-470 (2009) [C1]
2009Liu H, Jiang CC, Lavis CJ, Croft A, Dong L, Tseng H-Y, et al., '2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2', Molecular Cancer, 8 Article no. 122 (2009) [C1]
2008Zhang LJ, Hao YZ, Hu CS, Ye Y, Xie QP, Thorne RF, et al., 'Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells', Anti-Cancer Drugs, 19 159-166 (2008) [C1]
2008Mhaidat NM, Thorne RF, De Bock CE, Zhang XD, Hersey P, 'Melanoma cell sensitivity to docetaxal-induced apoptosis is determined by class III beta-tubulin levels', FEBS Letters, 582 267-272 (2008) [C1]
2008Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin', Clinical Cancer Research, 14 1659-1668 (2008) [C1]
2008Mhaidat NM, Thorne RF, de Bock CE, Zhang XD, Hersey P, 'Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels', FEBS LETTERS, 582 267-272 (2008) [C1]
2008Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein', Cancer Research, 68 834-842 (2008) [C1]
2008Hersey P, Zhang XD, 'Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma', Pigment Cell and Melanoma Research, 21 358-367 (2008) [C1]
2008Zhu B-K, Wang P, Zhang XD, Jiang CC, Chen LH, Kiejda KA, et al., 'Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells', Anti-Cancer Drugs, 19 189-200 (2008) [C1]
2008Jiang CC, Lucas K, Kiejda KA, Wade M, Debock CE, Thorne RF, et al., 'Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress', Cancer Research, 68 6708-6717 (2008) [C1]
2008Mhaidat NM, Thorne RF, Zhang XD, Hersey P, 'Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma', Apoptosis, 13 1505-1512 (2008) [C1]
2007Mhaidat NM, Zhang XD, Jiang CC, Hersey P, 'Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway', Clinical Cancer Research, 13 1308-1314 (2007) [C1]
2007Gillespie S, Kiejda KA, Mhaidat N, Yu FW, Thorne RF, Zhang XD, et al., 'Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response', Cancer Research, 67 5880-5888 (2007) [C1]
2007Chen LH, Jiang CC, Kiejda KA, Wang YF, Thorne RF, Zhang XD, Hersey P, 'Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response', Carcinogenesis, 28 2328-2336 (2007) [C1]
2007Mhaidat NM, Zhang XD, Allen J, Kiejda KA, Scott R, Hersey P, 'Temozolomide induces senescence but not apoptosis in human melanoma cells', British Journal of Cancer, 97 1225-1233 (2007) [C1]
2007Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P, 'Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2', Molecular Cancer Therapeutics, 6 752-761 (2007) [C1]
2007Yu FW, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P, 'Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1', Clinical Cancer Research, 13 4934-4942 (2007) [C1]
2007Jiang CC, Li HC, Gillespie S, Yu FW, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis', Cancer Research, 67 9750-9761 (2007) [C1]
2007Mhaidat NM, Thorne RF, Zhang XD, Hersey P, 'Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C', Molecular Cancer Research, 5 1073-1081 (2007) [C1]
2007Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P, 'Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma', Modern Pathology, 20 416-426 (2007) [C1]
2006Yu F, Watts RN, Zhang XD, Borrow JM, Hersey P, 'Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells', Anti-Cancer Drugs, 17 1151-1161 (2006) [C1]
2006Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al., 'Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand', Human Pathology, 37 1286-1294 (2006) [C1]
2006Gillespie S, Borrow J, Zhang XD, Hersey P, 'Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells', Apoptosis, 11 2251-2265 (2006) [C1]
2006Hersey P, Zhuang L, Zhang XD, 'Current strategies in overcoming resistance of cancer cells to apaptosis melanoma as a model', International Review of Cytology - A Survey of Cell Biology, 251 131-158 (2006) [C1]
2006Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P, 'Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin', Clinical Cancer Research, 12 1355-1364 (2006) [C1]
2006Zhang XD, Wu JJ, Gillespie S, Borrow JM, Hersey P, 'Cross resistance of melanoma to trail-induced apoptosis and chemotherapy', Update on Cancer Therapeutics, 1 435-441 (2006) [C1]
2005Gillespie S, Zhang XD, Hersey P, 'Variable expression of protein kinase CE in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis', Molecular Cancer Therapeutics, 4 668-676 (2005) [C1]
2005Wu JJ, Zhang XD, Gillespie S, Hersey P, 'Selection for TRAIL resistance results in melanoma cells with high proliferative potential', FEBS Letters, 579 1940-1944 (2005) [C1]
2005Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, et al., 'Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma', Journal of Clinical Pathology, 58 1163-1169 (2005) [C1]
2005Allen JD, Zhang XD, Scott CL, Boyle GM, Hersey P, Strasser A, 'Is Apaf-1 expression frequently abrogated in melanoma?', CELL DEATH AND DIFFERENTIATION, 12 680-681 (2005)
2004Zhang (Ext) XD, Gillespie SK, Hersey P, 'Staurosporine induces apoptosis of melanoma by both caspase-dependant and -independant apoptotic pathways', Molecular Cancer Therapeutics, 3 187-197 (2004) [C1]
2004Gillespie SK, Zhang XD, Hersey P, 'Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced aopootsis in melanoma cells', Molecular Cancer Therapeutics, 3 1651-1658 (2004) [C1]
2004Zhang XY, Zhang (Ext) XD, Borrow JM, Nguyen T, Hersey P, 'Translational Control of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Death Receptor Expression in Melanoma Cells', Journal of Biological Chemistry, 279 10606-10614 (2004) [C1]
2004Zhang (Ext) XD, Gillespie SK, Borrow JM, Hersey P, 'The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells', Molecular Cancer Therapeutics, 3 425-435 (2004) [C1]
2003Xu DZ, Gillespie SK, Borrow JM, Hersey P, 'The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis', Biochemical Pharmacology, 66 1537-1545 (2003) [C1]
2003Hersey P, Zhang (Ext) XD, 'Overcoming resistance of cancer cells to apoptosis', Journal of Cellular Physiology, 196 9-18 (2003) [C1]
2003Hersey P, Zhang XD, 'Resistance of follicular lymphoma cells to chemotherapy is more than just Bcl-2', CANCER BIOLOGY & THERAPY, 2 541-543 (2003)
2003Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P, 'Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria', ONCOGENE, 22 2869-2881 (2003)
2001Zhang X, Zhang X, Gray C, Nguyen T, Hersey P, 'Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria', Cancer Research, 61 7339-7348 (2001) [C1]
2001Hersey P, Zhang X, 'How melanoma cells evade trail-induced apoptosis', Nature Reviews Cancer, 1 142-150 (2001) [C1]
2001Franco A, Zhang X, Van Berkel E, Sanders J, Zhang X, Thomas W, et al., 'The role of NF-kB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells', The Journal of Immunology, 166 5337-5345 (2001) [C1]
2001Nguyen T, Zhang X, Hersey P, 'Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis', Clinical Cancer Research, 7 966s-973s (2001) [C1]
2000Thomas W, Zhang X, Franco A, Nguyen T, Hersey P, 'TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria', The Journal of Immunology, 165 No 10 5612-5620 (2000) [C1]
2000Zhang X, Nguyen T, Thomas W, Sanders J, Hersey P, 'Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types', FEBS Letters, 482 193-199 (2000) [C1]
2000Zhang X, Franco A, Nguyen T, Gray C, Hersey P, 'Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells', The Journal of Immunology, 164 No 8 3961-3970 (2000) [C1]
2000Nguyen T, Thomas W, Zhang X, Gray C, Hersey P, 'Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma', Forum: Trends in Experimental and Clinical Medicine, 10 243-252 (2000) [C3]
1999Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P, 'Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma', CANCER RESEARCH, 59 2747-2753 (1999)
1999Zhang XD, Hersey P, 'Expression of catenins and p120(cas) in melanocytic nevi and cutaneous melanoma: Deficient alpha-catenin expression is associated with melanoma progression', PATHOLOGY, 31 239-246 (1999)
Show 106 more

Conference (54 outputs)

YearCitationAltmetricsLink
2013Jin L, Li D, Wang CY, Tseng H-Y, Wilmott JS, Yosufi B, et al., 'PHLPP1 Deactivates Akt and has a Tumour Suppressive Role in Human Melanoma', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2013) [E3]
2013Guo ST, Lal F, Jiang CC, Wang CY, Farrelly M, Tseng H-Y, et al., 'Co-targeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cell by caspase-independent cell death.', CANCER RESEARCH, Washington, DC (2013) [E3]
2013Cheung BB, Sutton SK, Tan O, Koach J, Liu B, Liu T, et al., 'TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma', CANCER RESEARCH, Washington, DC (2013) [E3]
2013Tseng H-Y, Lai F, Jin L, Jiang CC, Kefford R, Long G, et al., 'Inhibition of Oncogenic BRAF Triggers Immunogenic Necrosis of Human Melanoma Cells', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2013) [E3]
2012Hersey P, Wroblewski D, Mijatov B, Zhang XD, Haass N, 'Effect of the BH3 mimetic ABT-737 on human melanoma cells to apoptosis induced by selective BRAF inhibitors.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2012) [E3]
2011Sadeqzadeh E, Hersey P, Zhang XD, Debock C, Boyd A, Burns GF, Thorne RF, 'Aberrant processing of Fat1 Cadherin in human cancer', Clinical Biochemistry, Mashhad, Iran (2011) [E3]

Co-authors: Rick Thorne

2011Hersey P, Wroblewski DJR, Lai FS, Jiang CC, Zhang XD, 'Targeting anti-apoptotic mechanisms for reversal of resistance to BRAF inhibitors in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
2011Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
2011Ye Y, Jin L, Wilmott J, Hu WL, Thorne RF, Dong L, et al., 'Phosphatidylinositol 4,5-Bisphosphate 5-Phosphatase A regulates PI3K/Akt signaling in human melanoma cells', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]

Co-authors: Rick Thorne

2010Watts RN, Hackett JA, Zhang XD, Hersey P, 'Proton pump inhibitor omeprazole and NAC complex induces apoptosis in melanoma cell lines', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Chen LH, Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, et al., 'Cystatin B inhibition of TRAIL-induced apoptosis is associated with protection of FLIPLfrom degradation by the E3 ligase itch human melanoma cells', Pigment Cell & Melanoma Research, Sydney, Australia (2010) [E3]
2010Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2010Jiang CC, Zhuang LQ, Dong L, Thorne RF, Lavis CJ, Hersey P, Zhang XD, 'Adaptation to ER stress as a driver of increased expression of Mcl-1 with melanoma progression', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]

Co-authors: Rick Thorne

2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
2010Zhang XD, Jiang CC, Lai F, Croft A, Tay KH, Thorne RF, et al., 'Apoptotic response of mutant B-RAF human melanoma cells to a B-RAF inhibitor involves increased splicing production of BimS', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]

Co-authors: Rick Thorne

2010Dong L, Jiang CC, Thorne RF, Yang F, Liu H, De Bock CE, et al., 'Transcriptional up-regulation of Mcl-1 by ETS1 down-stream of XBP-1 in melanoma cells upon ER stress', Pigment Cell & Melanoma Research, Sydney, Australia (2010) [E3]

Co-authors: Rick Thorne

2010Zhang XD, Jiang CC, Zhuang LQ, Hersey P, 'Adaptation to ER stress as a mechanism of resistance of melanoma to treatment', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Jiang CC, Lai FS, Hersey P, Zhang XD, 'Preferential splicing of BimS plays a predominant role in induction of apoptosis in human melanoma cells', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Salum De Oliveira C, Yan XG, Hersey P, Zhang XD, Thorne RF, 'The role of MIF signaling in melanoma progression', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]

Co-authors: Rick Thorne

2010Tay KH, Jiang CC, Tseng HY, Hersey P, Zhang XD, 'Rapid negative feedback regulation of CHOP contributes to resistance of melanoma cells to ER stress-induced apoptosis', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Wilmott J, Scolyer RA, Zhang XD, Hersey P, 'The role of p53, microRNA-149*, GSK-3 and MCL-1 in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Yang XM, Chen LH, Jiang CC, De Bock CE, Thorne RF, Hersey P, Zhang XD, '40p53 is up-regulated and plays a role in antagonizing p53-mediated apoptosis in human melanoma', Pigment Cell & Melanoma Research, Sydney, Australia (2010) [E3]

Co-authors: Rick Thorne

2010Wroblewski DJR, Zhang XD, Hersey P, 'Induction of endoplasmic reticulum stress and upregulation of Bcl-2 family proteins in melanoma cells by the BH3 mimetics obatoclax and ABT-737', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Croft A, Lai F, Jiang CC, Zhang XD, Hersey P, 'Active XBP1 levels may predict resistance of B-Raf V600E melanoma cell lines to PLX4720', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Lai F, Jiang CC, Hersey P, Zhang XD, 'Long-term exposure to the B-RAFV600E inhibitor PLX4720 results in melanoma cells with increased activation of ERK1/2 and high proliferation potential', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Becker TM, Philips S, Mijatov B, Pupo GM, Gowrishankar K, Kefford RF, et al., 'Analysis of oncogenic BRAF mediated Mcl-1 regulation in melanocytes', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Tseng HY, Jiang CC, Croft A, Tay KH, Yang F, Liu H, et al., 'Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis in human melanoma cells', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2009Zhang XD, Jiang CC, Kiejda KA, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', 7th World Congress on Melanoma, 5th Congress of the European Association of Dermato-Oncology (EADO): Final Program, Vienna, Austria (2009) [E3]

Co-authors: Kelly Kiejda

2009Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference, Lorne, VIC (2009) [E3]
2009Kairupan CF, Bowden NA, Ashton KA, Zhang XD, Hersey P, Scott R, 'Gene expression profiling in malignant melanoma', AMATA 2009, Katoomba, NSW (2009) [E3]
2008Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'The P53 splice variants, P53B and 40P53, are expressed in human melanoma cells and can differnetially regulate the transcription of P53 target genes in response to cisplatin', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
2008Zhang XD, Jiang CC, Avery-Kiejda KA, Lucas K, Wade M, Allen J, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', PIGMENT CELL & MELANOMA RESEARCH (2008) [E3]
2008Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK/ERK pathway potentiates adaptation of human melanoma to endoplasmic reticulum stress', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]

Co-authors: Kelly Kiejda

2008Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008, Brisbane, QLD (2008) [E3]
2008Jiang CC, Wade MA, Kiejda KA, Wang Y, Zhang XD, Hersey P, 'Up-regulation of MCL-1 is critical for survival of human melanoma cells upon ER stress', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]

Co-authors: Kelly Kiejda

2008Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Cooper WA, Zhang XD, et al., 'The glucose-regulated stress protein GRP78 is upregulated during progression of melanoma', PIGMENT CELL & MELANOMA RESEARCH (2008) [E3]
2007Zhang XD, Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Hersey P, 'Regulation of the BCL-2 family members BIM, PUMA and MCL-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]

Co-authors: Kelly Kiejda

2007Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'MEK/ERK-mediated regulation of the Bcl-2 family members Mcl-1, PUMA, and Bim contributes to survival of human melanoma cells', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
2007Jiang CC, Chen IH, Kiejda KA, Gillespie SK, Hersey P, Zhang XD, 'The unfolded protein response induced by tunicamycin or thapsigargin sensitizes human melanoma cells to trail-induced apoptosis by selective up-regulaton of trail-R2 on te cell surface', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]

Co-authors: Kelly Kiejda

2007Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by cisplatin', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
2007Kiejda KA, Zhang XD, Hersey P, 'The P53 splice variant, P53B, is widely expressed in human melanoma', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]

Co-authors: Kelly Kiejda

2007Hersey P, Zhang XD, Jiang CC, Chen LH, 'Endoplasmic stress (ER) in melanoma cells', Archives of Dermatological Research, Barcelona, Spain (2007) [E3]
2007Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK-ERK pathway potentiates adaptation of melanoma to endoplasmic reticulum stress', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]

Co-authors: Kelly Kiejda

2007Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Zhang XD, Hersey P, 'Regulation of the Bcl-2 family members Bim, PUMA and Mcl-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]

Co-authors: Kelly Kiejda

2006Kiejda KA, Zhang XD, Hersey P, 'Expression of P53 variants in human melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]

Co-authors: Kelly Kiejda

2006Kiejda KA, Zhang XD, Hersey P, 'p53 variants in human melanoma', 13th Annual p53 Workshop. Program & Abstracts, New York (2006) [E3]

Co-authors: Kelly Kiejda

2006Wang YF, Jiang CC, Kiejda KA, Zhang XD, Hersey P, 'Suppression of the BH3-only proteins BUM and PUMA by MEK/ERK signaling plays a crucial role in maintaining survival of melanoma cells', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]

Co-authors: Kelly Kiejda

2006Jiang CC, Wang YF, Kiejda KA, Zhang XD, Hersey P, 'CD133, A potential marker for cancer stem cells in melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]

Co-authors: Kelly Kiejda

2006Hersey P, Zhang XD, Gillespie S, 'Hurdles to overcome in treatment of melanoma by TRAIL', JOURNAL OF IMMUNOTHERAPY, Los Angeles, CA (2006)
2004Hersey P, Zhang XD, Wu JJ, Gillespie S, 'Cross resistance of melanoma cells to apoptosis induced by trail and chemotherapy', JOURNAL OF IMMUNOTHERAPY, San Francisco, CA (2004)
2004Hersey P, Zhang XD, Zhang XY, Borrow J, Gillespie S, 'Sensitising human melanoma cells to apoptosis induced by the immune system', JOURNAL OF INVESTIGATIVE DERMATOLOGY, Sydney, AUSTRALIA (2004)
2003Zhang XD, Gillespie SK, Hersey P, 'The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces apoptosis by triggering changes in mitochondrial membrane permeability of melanoma cells.', CLINICAL CANCER RESEARCH, BOSTON, MASSACHUSETTS (2003)
Show 51 more
Edit

Grants and Funding

Summary

Number of grants37
Total funding$5,448,039

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2014 (2 grants)

High Throughput Image Capture Platform for Translational Cancer Research$282,614
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$282,61420142014
GNo:G1400626

RIPK1 as a novel therapeutic target in melanoma$20,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Lei Jin, Professor Xu Dong Zhang
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020142014
GNo:G1301258

2013 (5 grants)

Functional consequences of epigenetic repression of PIB5PA in melanoma$359,250
Funding Body: Cancer Council NSW

Project Team
Professor Xu Dong Zhang, Dr Helen Rizos, Doctor Rick Thorne, Doctor Chen Chen Jiang
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$359,25020132015
GNo:G1200386

Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,250
Funding Body: Cancer Council NSW

Project Team
Professor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$359,25020132015
GNo:G1200388

Leica TP 1020 Automatic Tissue Processor for histology applications$35,000
Funding Body: NHMRC (National Health & Medical Research Council)

Ultra-Low Temperature Cryogenic Freezer$24,596
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Jude Weidenhofer, Doctor Rick Thorne, Doctor Kathryn Skelding, Doctor Nikki Verrills, Doctor Pradeep Tanwar, Associate Professor Phillip Dickson, Conjoint Associate Professor Murray Cairns, Professor Hubert Hondermarck, Professor Xu Dong Zhang, Associate Professor Estelle Sontag, Doctor Chen Chen Jiang, Associate Professor Liz Milward, Doctor Jean-Marie Sontag, Associate Professor Paul Tooney, Doctor Severine Roselli, Doctor Matt Dun, Doctor Chris Dayas, Doctor Lin Kooi Ong, Professor Dirk Van Helden, Mr Ben Copeland, Doctor Gabrielle Briggs, Emeritus Professor Leonie Ashman, Emeritus Professor John Rostas
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$24,59620132013
GNo:G1201189

2013 International Visitor - Guo$10,000
Funding Body: University of Newcastle

Project Team
Professor Xu Dong Zhang, Professor Sutang Guo
SchemeRole
DVCR International Visitor SupportChief Investigator
Total AmountFunding StartFunding Finish
$10,00020132013
GNo:G1301154

2012 (6 grants)

Targeting Histone Deacetylases to Overcome Resistance of BRAFV600E Melanoma Cells to Apoptosis$346,974
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Dr Tao Liu, Doctor Chen Chen Jiang, Doctor Rick Thorne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$346,97420122014
GNo:G1100133

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$292,300
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Conjoint Associate Professor Barbara Young, Professor Hubert Hondermarck, Emeritus Professor Leonie Ashman, Professor Xu Dong Zhang, Doctor Kelly Kiejda, Doctor Nikki Verrills, Doctor Jennette Sakoff, Ms Janine Lombard, Doctor Jude Weidenhofer, Doctor Pradeep Tanwar
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$292,30020122014
GNo:G1200798

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$143,39420122012
GNo:G1200555

Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$34,00020122012
GNo:G1100983

The Role of Phosphatidylinositol 4, 5-Bisphosphate 5-Phosphatase A (PIB5PA) in Regulation of PI3K/Akt Signalling in Melanoma$24,000
Funding Body: Hunter Medical Research Institute

Project Team
Professor Xu Dong Zhang, Doctor Chen Chen Jiang
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$24,00020122012
GNo:G1101121

A p53-Mediated Pro-Survival Signaling Pathway in Human Melanoma Progression and Resistance to Treatment$20,000
Funding Body: University of Newcastle

Project Team
Professor Xu Dong Zhang, Doctor Rick Thorne, Doctor Chen Chen Jiang
SchemeRole
Near Miss GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,00020122012
GNo:G1200672

2011 (5 grants)

Overcoming resistance of human metastatic melanoma to treatment$570,640
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor Xu Dong Zhang
SchemeRole
Research FellowshipsChief Investigator
Total AmountFunding StartFunding Finish
$570,64020112015
GNo:G1000048

Targeting pro-survival mechanisms to sensitize human melanoma to immunotherapy$359,250
Funding Body: Cancer Council NSW

Project Team
Professor Xu Dong Zhang, Doctor Ming Yang
SchemeRole
Research ProgramChief Investigator
Total AmountFunding StartFunding Finish
$359,25020112013
GNo:G1000379

Overcoming Resistance of Metastatic Melanoma to Treatment: 53 regulation of Mcl-1 via a microRNA-Mediated Pathway in Melanoma progression and Resistance to Chemotherapy$123,498
Funding Body: Cancer Institute NSW

Project Team
Professor Xu Dong Zhang
SchemeRole
Career Development FellowshipChief Investigator
Total AmountFunding StartFunding Finish
$123,49820112014
GNo:G1000815

Regulation of BimS splicing in response of human melanoma cells to inhibition of BRAFVV600E$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Chen Chen Jiang, Professor Xu Dong Zhang
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00020112011
GNo:G1000988

Targeting Pro-Survival Mechanisms to Sensitize Human Melanoma to Immunotherapy$25,000
Funding Body: University of Newcastle

Project Team
Professor Xu Dong Zhang, Doctor Ming Yang
SchemeRole
Near Miss GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020112011
GNo:G1001046

2010 (4 grants)

Transcriptional regulation of the expression of Mcl-1 in melanoma cell under ER stress$144,300
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Professor Peter Hersey, Professor Xu Dong Zhang, Doctor Li Dong
SchemeRole
Training (Postdoctoral) Fellowships - Australia-China Exchange FellowshipsInvestigator
Total AmountFunding StartFunding Finish
$144,30020102013
GNo:G0190308

Melanoma Institute Australia Translational Research Program$58,405
Funding Body: Cancer Institute NSW

Project Team
Professor Graham Mann, Professor John Thompson, Professor Rick Kefford, Professor Richard Scolyer, Professor Scott Menzies, Associate Professor Andrew Spillane, Conjoint Professor Peter Hersey, Dr Helen Rizos, Professor Xu Dong Zhang, Professor Richard Christopherson
SchemeRole
Translational Program GrantChief Investigator
Total AmountFunding StartFunding Finish
$58,40520102015
GNo:G1200975

Targeting Pro-Survival Mechanisms to Sensitize Human Melanoma to Immunotherapy$48,200
Funding Body: Cancer Institute NSW

Project Team
Professor Xu Dong Zhang
SchemeRole
Research Innovation GrantsChief Investigator
Total AmountFunding StartFunding Finish
$48,20020102010
GNo:G0190555

The role of micro-RNA-149 in Regulation of Mcl-1 in Human Melanoma under stress$20,000
Funding Body: Hunter Children`s Research Foundation

Project Team
Doctor Chen Chen Jiang, Professor Xu Dong Zhang
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020102010
GNo:G0900189

2009 (4 grants)

Targeting adaptive mechanisms to endoplasmic reticulum stress in melanoma$491,250
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Rick Thorne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$491,25020092011
GNo:G0188902

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$272,000
Funding Body: Cancer Council NSW

Project Team
Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Kelly Kiejda
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$272,00020092011
GNo:G0188913

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$75,000
Funding Body: Cancer Australia

Project Team
Doctor Kelly Kiejda, Professor Xu Dong Zhang, Conjoint Professor Peter Hersey
SchemeRole
Priority-driven Collaborative Cancer Research SchemeInvestigator
Total AmountFunding StartFunding Finish
$75,00020092009
GNo:G0188914

FACSAria$30,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Rick Thorne, Doctor Severine Roselli, Professor Xu Dong Zhang, Dr Charles De Bock, Conjoint Professor Peter Hersey, Professor Gordon Burns
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$30,00020092009
GNo:G0189846

2008 (1 grants)

Colibri high-performance LED illumination system for fluorescence live cell microscopy$23,225
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Rick Thorne, Dr Charles De Bock, Professor Xu Dong Zhang, Doctor Lisa Lincz, Professor Gordon Burns, Conjoint Professor Peter Hersey, Professor Dirk Van Helden, Conjoint Professor Keith Jones, Professor Roger Smith
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$23,22520082008
GNo:G0188545

2007 (4 grants)

Characterization of p53 isoforms in human melanoma: do they play a role in chemoresistance?$75,000
Funding Body: Cure Cancer Australia Foundation

SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$75,00020072007
GNo:18105190

The role of p53 Isoforms in chemoresistances of human melanoma$20,000
Funding Body: Hunter Medical Research Institute

Project Team
Professor Xu Dong Zhang, Doctor Kelly Kiejda
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,00020072007
GNo:G0187239

The role of p53 isoforms in chemoresistance of human melanoma. $0
Funding Body: Newcastle Mater Misericordiae Hospital

SchemeRole
Small GrantChief Investigator
Total AmountFunding StartFunding Finish
$020072007
GNo:18105231

molecular predictors of risk, progression and treatment response in melanoma$0
Funding Body: National Health & Medical Research Council

SchemeRole
Program GrantInvestigator
Total AmountFunding StartFunding Finish
$020072007
GNo:18105827

2006 (1 grants)

PRC - Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM)$621,143
Funding Body: University of Newcastle

Project Team
Professor Pablo Moscato, Professor Rodney Scott, Emeritus Professor John Rostas, Professor John Forbes, Conjoint Professor Peter Hersey, Conjoint Professor Stephen Ackland, Conjoint Professor Wayne Smith, Emeritus Professor Peter Dunkley, Emeritus Professor Leonie Ashman, Professor John Attia, Associate Professor Phillip Dickson, Associate Professor Liz Milward, Professor Alistair Sim, Associate Professor Paul Tooney, Associate Professor Regina Berretta, Conjoint Professor David Sibbritt, Conjoint Professor Chris Levi, Professor Xu Dong Zhang, Conjoint Associate Professor Patricia Crock, Conjoint Associate Professor Jeannette Lechner-Scott
SchemeRole
Priority Research CentreInvestigator
Total AmountFunding StartFunding Finish
$621,14320062013
GNo:G0186919

2005 (4 grants)

Overcoming resistance of human melanoma to chemotherapy$492,750
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Professor Peter Hersey, Professor Xu Dong Zhang, Dr John Allen
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$492,75020052007
GNo:G0183933

PULSE Young Medical Researcher of the Year Award$5,000
Funding Body: Hunter Medical Research Institute

Project Team
Professor Xu Dong Zhang
SchemeRole
PULSE Early Career Researcher of the Year AwardChief Investigator
Total AmountFunding StartFunding Finish
$5,00020052005
GNo:G0184902

Overcoming Resistance of Melanoma to Chemotherapy$0
Funding Body: National Health & Medical Research Council

SchemeRole
ProjectChief Investigator
Total AmountFunding StartFunding Finish
$020052007
GNo:18105841

Overcoming Resistance of Melanoma to Chemotherapy: Are Melanoma Stem Cells Key Targets? $0
Funding Body: Cancer Institute NSW

SchemeRole
Career Development and Support FellowshipChief Investigator
Total AmountFunding StartFunding Finish
$020052007
GNo:18105807

2003 (1 grants)

Regulation of TNF Apoptosis Inducing Ligand (TRAIL) Receptor Expression in Human Melanoma Cells.$17,000
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Peter Hersey, Professor Xu Dong Zhang
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$17,00020032003
GNo:G0182640
Edit

Research Supervision

Number of current supervisions6
Total current UoN PhD EFTSL3

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Current Supervision

CommencedProposed
Completion
ProgramSupervisor TypeResearch Title
20142018PhD (Medical Biochemistry)Principal SupervisorINPP4B as a Novel Therapeutic Target in Melanoma and Colorectal Cancer
20142018PhD (Medical Biochemistry)Principal SupervisorOvercoming Resistance of Melanoma to Treatment
20142018PhD (Medical Biochemistry)Co-SupervisorProNGF in Pancreatic Cancer
20142018PhD (Medical Biochemistry)Principal SupervisorFunctional Consequences of Epigenetic Repression of PIB5PA in Melanoma
20112015PhD (Surgical Science)Principal SupervisorInositol Polyphosphate 4-Phosphatese 11 (INPP4B) Promotes PI3K Signaling and Functions as an Oncogenic Regulator in Human Colon Cancer and Melanoma
20082012PhD (Surgical Science)Co-SupervisorOvercoming Resistance of Melanoma Cells to Apoptosis

Past Supervision

YearProgramSupervisor TypeResearch Title
2014PhD (Surgical Science)Principal SupervisorRegulation of Apoptosis Induced by Targeting the RAF/MEK/ERK Pathway in Human Melanoma
2014PhD (Surgical Science)Principal SupervisorTargeting Adaptive Mechanisms to Endoplasmic Reticulum Stress in Melanoma
2013PhD (Medical Biochemistry)Co-SupervisorThe Role of MIF in Melanoma Progression
2012PhD (Surgical Science)Co-SupervisorSensitising Human Melanoma Cells to TRAIL-induced Apoptosis
2008PhD (Surgical Science)Consultant SupervisorRegulation of Endoplasmic Reticulum Stress Induced Apoptosis in Human Melanoma
2007PhD (Surgical Science)Co-SupervisorOvercoming Resistance of Human Melanoma to Chemotherapy-Induced Apoptosis
Edit

Professor Xu Dong Zhang

Work Phone(02) 4921 8906
Cell / Mobile Phone0422621827
Fax(02) 4921 7311
Email
PositionProfessor
Melanoma Research Laboratory
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
The University of Newcastle, Australia
Office
LS3-49,
Life Sciences Building,
Callaghan
University Drive
Callaghan NSW 2308
Australia
URL:www.newcastle.edu.au/profile/xu-zhang